Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

OncoCyte Corporation (OCX) had Revenue of $2.14M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$2.14M
Net Income	$-6.67M
Cost of Goods Sold	$0.81M
Gross Profit	$1.32M
Operating Expenses	$8.94M
Operating Income	$-6.80M
Non-Operating Income/Expense	$0.13M
Pre-Tax Income	$-6.67M
Normalized Pre-Tax Income	$-6.67M
Income after Taxes	$-6.67M
Income from Continuous Operations	$-6.67M
Consolidated Net Income/Loss	$-6.67M
Normalized Income after Taxes	$-6.67M
EBIT	$-6.80M
EBITDA	$-6.31M
Weighted-Average Shares Outstanding (Basic)	25.69M
Weighted-Average Shares Outstanding (Diluted)	25.69M
Earnings per Share (EPS) (Basic)	$-0.26
Earnings per Share (EPS) (Diluted)	$-0.26
Balance Sheet Financials
Current Assets	$36.26M
Property, Plant, and Equipment	$4.57M
Long-Term Assets	$24.10M
Total Assets	$60.36M
Current Liabilities	$9.68M
Long-Term Debt	$2.07M
Long-Term Liabilities	$40.46M
Total Liabilities	$50.14M
Common Equity	$10.22M
Tangible Shareholders Equity	$-4.38M
Shareholders Equity	$10.22M
Common Shares Outstanding	28.60M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-5.86M
Cash Flow from Investing Activities	$-0.31M
Cash Flow from Financial Activities	$28.56M
Beginning Cash	$10.34M
End Cash	$32.73M
Increase/Decrease in Cash	$22.39M
Stock-Based Compensation	$0.47M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.75
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.17
Debt to Equity Ratio	0.20
Gross Margin	61.97%
Operating Margin	-318.01%
EBIT Margin	-318.01%
EBITDA Margin	--
Pre-Tax Profit Margin	-312.02%
Profit Margin	-312.02%
Free Cash Flow	$-6.17M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.04
Inventory Turnover	1.77
Receiveable Turnover	0.60
Days Sales in Receivables	149.02
Return on Equity	-65.29%
Return on Tangible Equity	152.24%
Return on Assets	-11.05%
Return on Investments	-54.27%
Book Value Per Share	$0.36
Free Cash Flow per Share	$-0.24
Operating Cash Flow per Share	$-0.23

Data from Zacks Investment Research, Inc.